| Literature DB >> 31541121 |
Simone Sidoli1,2, Mariana Lopes1,3, Peder J Lund1, Naomi Goldman4,5, Maria Fasolino4, Mariel Coradin1,6, Katarzyna Kulej1, Natarajan V Bhanu1, Golnaz Vahedi4, Benjamin A Garcia7.
Abstract
Histone post-translational modifications (PTMs) contribute to chromatin accessibility due to their chemical properties and their ability to recruit enzymes responsible for DNA readout and chromatin remodeling. To date, more than 400 different histone PTMs and thousands of combinations of PTMs have been identified, the vast majority with still unknown biological function. Identification and quantification of histone PTMs has become routine in mass spectrometry (MS) but, since raising antibodies for each PTM in a study can be prohibitive, lots of potential is lost from MS datasets when uncharacterized PTMs are found to be significantly regulated. We developed an assay that uses metabolic labeling and MS to associate chromatin accessibility with histone PTMs and their combinations. The labeling is achieved by spiking in the cell media a 5x concentration of stable isotope labeled arginine and allow cells to grow for at least one cell cycle. We quantified the labeling incorporation of about 200 histone peptides with a proteomics workflow, and we confirmed that peptides carrying PTMs with extensively characterized roles in active transcription or gene silencing were in highly or poorly labeled forms, respectively. Data were further validated using next-generation sequencing to assess the transcription rate of chromatin regions modified with five selected PTMs. Furthermore, we quantified the labeling rate of peptides carrying co-existing PTMs, proving that this method is suitable for combinatorial PTMs. We focus on the abundant bivalent mark H3K27me3K36me2, showing that H3K27me3 dominantly represses histone swapping rate even in the presence of the more permissive PTM H3K36me2. Together, we envision this method will help to generate hypotheses regarding histone PTM functions and, potentially, elucidate the role of combinatorial histone codes.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31541121 PMCID: PMC6754405 DOI: 10.1038/s41598-019-49894-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Overview of the workflow and representative result spectra. (A) Rationale of the metabolic labeling principle; accessible chromatin has higher nucleosome turnover and thus it is labeled with higher rate as compared to silenced heterochromatin. Labeling is represented with the blue color. (B) Schematic of the workflow. Cells are grown in culture for a relatively short amount of time (1–3 days) with selected isotopically heavy amino acids (in this work, arginine) and then processed by using our in-house workflow for canonical histone PTM analysis. Relative quantification (relative PTM abundance and heavy/light ratio) is performed automatically by our in-house software EpiProfile[30]. (C) Full MS spectrum of the peptide of histone H3 KSTGGKAPR (aa 9–17) carrying one acetyl group (on the left) or one trimethyl group (on the right). Evidently, the peptide in its trimethylated form has a lower % heavy arginine incorporation. (D) MS/MS spectrum of the same peptide carrying one acetyl group, co-isolating the light and the heavy form. The fragment ions can be used to confirm the relative amount of labeling even in presence of isobaric forms (K9ac vs K14ac). Panel A and B were produced, in part, by using Servier Medical Art (http://smart.servier.com/). Servier Medical Art is licensed under a Creative Commons Attribution 3.0 License (CC BY 3.0 license: https://creativecommons.org/licenses/by/3.0/). The color of the images downloaded was modified to fit our figure.
Figure 2Labeling incorporation as function of time. (A) Percentage of labeling incorporation on all detectable 219 peptides after 1 day vs 2 days of growth in labeling media (left) or after 1 day vs 3 days of labeling (right) (correlation p-value 10e-26 and 10e-12, respectively). (B) Labeling incorporation on all detectable peptides represented as box plot. (C) Labeling incorporation of the peptide of histone H3 KSTGGKAPR (aa 9–17) in all its modified forms. Cells were labeled after being synchronized and (D) not synchronized. (E) Labeling incorporation of the histone H3 residues hosting the most abundant trimethyl and acetyl marks. The comparison considers only peptides modified with a single PTM; e.g. does not include hybrid modified peptides such as H3K9me3K14ac. (F) Labeling incorporation of the histone H4 peptide GKGGKGLGKGGAKR (aa 4–17) modified with a single acetylated residue. Significance represented between H4K5ac and the other marks. All significance estimations are based on a two-tail heteroscedastic t-test (significant when p-value < 0.05).
Figure 3Regulation of PTM relative abundance and labeling rate upon drug treatment. (A) Relative abundance of the most abundant acetylations of histone H3 and H4 in wild type and HDAC inhibitor (HDACi) treated cells. (B) Relative abundance of representative modified forms of histone H3 regulated during treatment with inhibitors. All data were extracted after 2 days of labeling. All significance estimations are based on a two-tail heteroscedastic t-test (significant when p-value < 0.05). (C) Correlation analysis of fold change regulation (not significant) of the relative abundance of histone peptides after treating cells with EZH2 inhibitor (x-axis) vs the fold change of labeling incorporation (y-axis). The y-axis shows very minor changes, indicating that the regulation of PTM abundance is independent from the labeling incorporation. (D) Same correlation analysis using the HDAC inhibitor Panobinostat (not significant). (E) Labeling incorporation of the major acetylated peptides of histone H3 and H4 in wild type and HDACi treated cells.
Figure 4Validation of the link PTM – chromatin state via genomics analysis. (A) Relative abundance of the five selected PTMs of histone H3 at day 1 to 3 of EL4 cell culture. (B) Labeling incorporation of the five representative marks. P-value is calculated by comparing H3K27me3 with the other PTMs at day 1. All significance estimations are based on a two-tail heteroscedastic t-test (significant when p-value < 0.05). (C) Description of how the following data were retrieved; panels D–F include the intersection of the reads obtained both by ChIP-seq and either ATAC-seq or RNA-seq. (D) Number of peaks intersecting in ChIP-seq and ATAC-seq data. (E) Intersection (counted base pairs) of genomics regions covered by both ChIP-seq and RNA-seq or (F) ATAC-seq.
Figure 5Analysis of labeling incorporation of multiply modified histone proteins. (A) Relative labeling incorporation at day 1–3 of the two peptides of histone H3 with the largest number of combinatorial isoforms, KSTGGKAPR (aa 9–17) and KSAPATGGVKKPHR (aa 27–40). Highlighted in red, peptide carrying both flanking modifications. P-value is calculated as paired t-test across the three days. All data were extracted after 2 days of labeling. All significance estimations are based on a two-tail heteroscedastic t-test (significant when p-value < 0.05). (B) Same representation for all the modified states of the peptide GKGGKGLGKGGAKR of histone H4, containing all the amino acid residues with the highest amount of acetylation. (C) Example of co-existing acetylations on the peptide of histone H3 KQLATKAAR (aa 18–26). The doubly acetylated form has higher labeling incorporation rate. (D) Relative incorporation of heavy labeled histidine of the differently modified forms of histone H3 N-terminal tails.